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Background: 11 patients were referred to our Molecular Genetics Department at the Royal Devon and Exeter
Hospital between 2000-2012 with a physician’s diagnosis of remitting diabetes. Our aim was to identify patients
with remitting diabetes whose clinical presentation is not explained by any known aetiology of diabetes.
Methods: We obtained longitudinal clinical data on all 11 patients from the hospital records. All patients were
aged between 0.5 and 35 years at diagnosis. We applied clinical criteria derived from the literature to establish
1) definite diabetes, 2) diabetes initially severe-requiring treatment with insulin, 3) remission of diabetes, and
4) exclusion of known causes of remitting diabetes.
Results: 10 out of 11 patients had an alternative explanation for their remission or a clear diagnosis was not
identified. We identified a single patient with idiopathic remitting diabetes using these criteria. The patient was a
white Caucasian female diagnosed aged 15 with symptoms of diabetes, laboratory glucose of 21.2 mmol/L and
HbA1c 134 mmol/mol. Her BMI was 23.6 kg/m2. She was treated with basal bolus insulin but discontinued two
years after diagnosis due to hypoglycaemia. 13 years post diagnosis, she had a normal oral glucose tolerance
test during pregnancy (fasting glucose 4.5 mmol/L, 2 hr glucose 4.8 mmol/L) and an HbA1c of 30 mmol/mol.
This patient does not appear to have Type 1 or Type 2 diabetes, and furthermore does not fit into current
classifications of diabetes.
Conclusions: Idiopathic remitting diabetes is rare but does exist. Strict clinical criteria are important to ensure
patients have a robust clinical diagnosis. Identification of more patients with idiopathic remitting diabetes will
enable further study of the clinical course of this syndrome. Applying these strict criteria will allow the identification
of patients with remitting diabetes to assess its aetiology.
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Diabetes is a heterogeneous disease that can occasionally
remit. In the majority of remitting cases a cause can be
identified. Examples include patients with Type 2 diabetes
who lose weight through severe caloric restriction [1] or
have had gastric bypass surgery [2], those with Type 1
diabetes who are in the honeymoon period [3], transient
neonatal diabetes due to a methylation abnormality in
chromosome 6q24 [4], and patients of African or Hispanic
origin with ketosis-prone diabetes [5]. Rarely, patients ini-
tially assumed to have Type 1 diabetes have managed to* Correspondence: A.T.Hattersley@exeter.ac.uk
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unless otherwise stated.maintain euglycaemia without treatment and have stopped
using insulin for longer than would be expected of the
honeymoon period [6]. This appears to be a unique form
of diabetes that does not fit into the current classification
of diabetes [7] and needs to be differentiated from other
types.
If we could identify patients with idiopathic remitting
diabetes, we would have an opportunity to study these
patients to establish the cause of their diabetes and why it
remits. At present there are no distinguishing clinical cri-
teria to differentiate idiopathic remitting diabetes from
other forms of diabetes.
Our aim was to identify patients with idiopathic remitting
diabetes using robust clinical criteria. We systematicallyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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We searched all referrals to our centre at the University
of Exeter Medical School Clinical Research Facility (n >
15,000) between 2000 – 2012 for patients with a physi-
cian’s diagnosis of remitting diabetes, diagnosed between
the ages of 0.5 – 35 years using the search terms remit,
remit*, remis* in the database of referrals, excluding the
2 patients we have previously described [6].
Data collection
We gathered longitudinal data from patients’ clinical re-
cords. We established patients’ clinical characteristics –
age of diagnosis, ethnic origin, body mass index, mode of
treatment, duration of treatment with insulin and how
long they had been in remission. In addition we deter-
mined HbA1c and/or laboratory glucose at diagnosis and
in remission, C-peptide or urinary C-peptide/creatinine
ratio, and GAD/IA2 autoantibodies.
Criteria
We then applied criteria to this cohort of 11 patients that
defined patients with a definite diagnosis of diabetes, ini-
tial severe diabetes – requiring treatment with insulin, def-
inite remission, and excluded other forms of diabetes that
can remit in order to find patients with true idiopathic re-
mitting diabetes. These criteria were derived from studies
in the literature.
Diagnostic Criteria for Idiopathic Remitting Diabetes:
−Aged over 6 months or less than 35 years at diagnosis
−White Caucasian
−HbA1c laboratory glucose diagnostic of diabetes
−BMI less than 30 kg/m2
−Marked fasting hyperglycaemia (to exclude
glucokinase-MODY) and requiring treatment with
insulin from diagnosisTable 1 Known types of remitting diabetes and the criteria app
Recognised forms of remitting diabetes
Type 1 diabetes in the honeymoon period
Type 2 diabetes with weight loss
Transient neonatal diabetes
Ketosis-prone atypical diabetes
Stress induced hyperglycaemia or steroid-induced hyperglycaemia−4 consecutive years without insulin treatment and
HbA1c in the normal range
−Other forms of remitting diabetes excluded (Table 1)Definite diagnosis of diabetes
Patients should have a definite biochemical diagnosis of
diabetes. We used WHO criteria based either on glucose
(random glucose greater than 11.1 mmol/L with symp-
toms suggestive of diabetes, fasting glucose greater than
7.0 mmol/L, or a 2 hour glucose greater than 11.1 mmol/L)
[8] or HbA1c ≥ 6.5% (48 mmol/mol) [9].Diabetes initially severe – requiring treatment with insulin
Treatment is a marker of the severity of initial hypergly-
caemia especially in young patients diagnosed before
35 years of age. We wanted there to be clear remission
from initially marked hyperglycaemia. A patient requir-
ing treatment with insulin from diagnosis is more likely
to have marked hyperglycaemia and less likely to have
Type 2 diabetes [10].Definite remission
To have clear remission the patients should be able to
stop all diabetes treatment and have normal glucose tol-
erance (HbA1c < 6.5%/48 mmol/mol). Type 1 diabetes is
associated with a honeymoon period where insulin se-
cretion is improved. This can lead to remission although
most patients continue to take some insulin.
A period of remission of greater than 4 years is unusual
for the honeymoon period. Previous studies have shown
that 10% of patients with Type 1 diabetes are off insulin
12 months after initially commencing insulin [11]. An-
other study defined remission as an insulin dose of ≤ 0.3
units/kg/day with an HbA1c in the normal range, and
found a prevalence of duration of remission of greater
than 4 years of 2.5% in a sample of 362 patients [12].
We used a stricter definition of remission as defined by
withdrawal of all treatment for diabetes for 4 years, with
an HbA1c < 6.5% (48 mmol/mol) during this period.lied to define them
Defining criteria
GAD/IA2 positive
Remission within four years of diagnosis
Obesity at diagnosis with subsequent weight loss or bariatric surgery
Diabetes diagnosed under 6 months of age
Non-Caucasian
Diagnosed at a time of extreme physiological stress e.g. acute illness
Concurrent glucocorticoid use around the time of diagnosis
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Our criteria excluded patients with a BMI above 30 kg/m2
who are those more likely to have Type 2 diabetes [13]. In
obese patients any remission may be due to increased
insulin sensitivity after weight loss [1]. Our patients
were aged between 6 months and 35 years. An age over
6 months excludes transient neonatal diabetes [4] and
an age at diagnosis of greater than 35 years is used by
the Royal College of General Practitioners to identify
patients more likely to have Type 2 diabetes [14]. Pa-
tients of non-European ancestry may have ketosis-prone
diabetes, a form of diabetes that can remit [5,15,16], and
so our criteria only includes patients of White European
ancestry. We also excluded patients with stress hyper-
glycaemia [17] i.e. due to acute illness or those with
hyperglycaemia secondary to corticosteroid use [18].
We thus defined idiopathic remitting diabetes as a non-
obese, White European patient aged between 6 months
and 35 years with a clear documented diagnosis of dia-
betes, treated with insulin from diagnosis, who had not re-
quired treatment for a period of 4 years or longer, with an
HbA1c in the normal range when in remission, not on
corticosteroids at the time of diagnosis.
Results
Most patients had an alternative reason for remission
We identified 11 patients referred with remitting dia-
betes. Our diagnostic criteria excluded 10 out of the 11
patients (Figure 1). All our patients were White Euro-
pean, aged less than 35 years at diagnosis, but none aged
less than 6 months. 2 patients did not have a confirmed
diagnosis of diabetes mellitus, one of the patients having
only a capillary glucose value but no laboratory glucose
or HbA1c. In total, 3 patients had a possible diagnosis of
type 2 diabetes; 2 patients with a BMI above 30 kg/m2
and 1 patient treated with oral hypoglycaemic agents
from diagnosis. 1 patient had a transient hyperglycaemia
after a course of oral steroids.
1 patient had true idiopathic remitting diabetes
Application of our diagnostic criteria identified one pa-
tient with idiopathic remitting diabetes (Figure 1). This
was a female patient diagnosed aged 15, after presenting
with symptomatic diabetes and a period of rapid weight
loss of approximately 12 – 15 kg over 2.5 months. Her la-
boratory glucose at diagnosis was 23 mmol/L and HbA1c
was 14.4% (134 mmol/mol). Her BMI was 23.6 kg/m2. She
was commenced on basal bolus insulin and remained on
treatment for two years. She then stopped treatment due
to hypoglycaemia; her HbA1c was 5.4% (36 mmol/mol).
She had an oral glucose tolerance test aged 28 (fasting glu-
cose 4.5 mmol/L, 2 hour glucose 4.8 mmol/L) during
pregnancy. She has remained off treatment to date. There
was no significant weight loss in the 15 years post-diagnosis making insulin resistance unlikely. GAD, IA2
and ZnT8 antibodies were negative, and she had pre-
served C-peptide with a UCPCR 9.98 nmol/mol (5th and
95th percentiles for non-diabetic controls 0.58 mmol/mol
and 10.37 mmol/mol respectively) [19]. She has a family
history of diabetes, with a maternal grandmother diag-
nosed with Type 2 diabetes, and a paternal uncle with
Type 1 diabetes diagnosed in his teens. Neither parent has
had diabetes. She has no siblings but her son, currently
aged 3, does not have diabetes. Targeted next-generation
sequencing of the 29 genes known to cause monogenic
diabetes has not identified a mutation [20]. Her case does
not fit in with any of the known causes of diabetes that re-
mit. According to our criteria, the patient has idiopathic
remitting diabetes, with her remission lasting even during
pregnancy.
Discussion
Idiopathic remitting diabetes is rare
We have identified a cause for remission in 10 out of 11
patients with a physician’s diagnosis of remitting dia-
betes. Patients were either misdiagnosed or had another
possible cause for their remitting hyperglycaemia. We
identified a single patient with idiopathic remitting dia-
betes, on insulin for 2 years post diagnosis, and then re-
mitting and remaining off treatment for the following
15 years, even during pregnancy. Idiopathic remitting dia-
betes is rare, as we have identified a single case from a
database of >15,000 patients. Remitting diabetes of a simi-
lar pattern has been described by our group previously, af-
fecting two young sibling boys of European ancestry [6].
We have not found any other cases in the literature.
Strict criteria are necessary to identify patients who may
have another cause for remission
Strict criteria have identified only 1 patient with idiopathic
remitting diabetes. It may be that within our cohort of pa-
tients there are other patients with the same disease
process who have not been identified due to the strict na-
ture of our criteria. Inclusion of patients with a BMI above
30 kg/m2, for example, may yield a larger number of pa-
tients with idiopathic remitting diabetes, although as the
average population BMI is increasing, there are likely to
be more patients with Type 2 diabetes. However, it is only
through using such strict criteria that we can be sure that
there is not an alternative form of diabetes until more
patients have been identified and studied to establish im-
proved criteria, perhaps including other clinical character-
istics, biomarkers or genetic testing.
Case discussion
Remitting diabetes vs Type 1 diabetes
Our patient with idiopathic remitting diabetes does not
have typical Type 1 diabetes. The prolonged length of
Figure 1 Flow chart showing referrals and the application of diagnostic criteria to diagnose idiopathic remitting diabetes.
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betes in the honeymoon period. Whilst the honeymoon
period is a common phenomenon in Type 1 diabetes, it
is rare that it would continue for longer than 4 years
and virtually all patients in a Swedish study looking at
the length or remission after an initial diagnosis of Type
1 diabetes needed insulin therapy within this time period
[12]. Our patient had preserved C-peptide secretion
13 years after her initial diagnosis of diabetes. This sug-
gests that beta cell function was only temporarily dis-
rupted. Previous work has demonstrated that patients
this many years after a diagnosis of Type 1 diabetes are
unlikely to be producing endogenous insulin in suchquantities [21]. In addition, our patient has not devel-
oped diabetic ketoacidosis in the 15 years of her remis-
sion despite no insulin treatment. Negative GAD and
IA2 antibodies also support that this is unlikely to be
Type 1 diabetes [22]. The previous case report has also
not identified insulin, islet cell or GAD autoantibodies in
these patients [6].
Remitting diabetes vs Type 2 diabetes
This is not likely to be Type 2 diabetes in remission as our
patient had a normal BMI at diagnosis in her teens. It is un-
usual to have an insulin requirement for 2 years after initial
presentation before developing insulin independence in the
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insulin resistance, and patients with risk factors may de-
velop gestational diabetes [23]. Our patient has not re-
lapsed, even after 13 years without insulin treatment and
has even had normal glucose tolerance in pregnancy.Rare forms of diabetes that can remit
The manner in which our patient’s diabetes progressed
does not fit with glucokinase-MODY. Patients with
glucokinase-MODY can be mistaken for having diabetes
and can have an HbA1c in the diagnostic range [24].
These patients are often initially treated with insulin
(perhaps due to their young age at diagnosis), then stop
treatment due to perceived improvement in HbA1c and
therefore appear to remit. HbA1c incorrectly diagnoses
more patients who have glucokinase-MODY with dia-
betes compared with fasting glucose [24]. We have ex-
cluded glucokinase-MODY as our patient had markedly
high initial glucose values which are now normal, evi-
denced also by the normal fasting glucose values our pa-
tient had in her OGTT in pregnancy (lower fasting
glucose than seen in glucokinase-MODY [25]).
Ketosis-prone diabetes is another form of diabetes that
can appear to remit, with patients developing episodes of
acute hyperglycaemia and ketosis, requiring insulin and
intermittent periods with no insulin-dependence [5]. Pa-
tients with remitting diabetes should be of white Caucasian
ancestry to distinguish them from a possible diagnosis of
ketosis-prone diabetes, which is well described in patients
of non-Caucasian ancestry [16].Aetiology of idiopathic remitting diabetes
It is clear that more research is needed to establish the biol-
ogy of this form of diabetes. Whilst it is difficult to establish
an aetiology with so few cases described, it could be that it
is due to a transient viral illness, or a burnt out auto-
immune process which has been seen in other autoimmune
conditions such as juvenile idiopathic arthritis [26] and
membranous glomerulonephritis [27]. One theory postu-
lates that Type 1 diabetes is a relapsing-remitting disease
process with an interplay of autoreactive effector T cells
and regulatory T cells dictating whether diabetes progresses
or remits [28]. Parallels can also be drawn with multiple
sclerosis, some patients having a single episode, others re-
lapsing several times, and others with a primary progressive
disease pattern [29]. An age of diagnosis greater than
6 months excludes transient neonatal diabetes, but this
may be an area to look for comparisons in further research.
Further exome sequencing of family members could un-
cover an as of yet undiscovered genetic cause, however
given the absence of diabetes in the patient and her first de-
gree relatives, this seems inappropriate.Limitations of the study
We have relied on data from clinical records which may
be inaccurate or incomplete despite confirmation from
hospital laboratories.
There are limitations to the way in which our criteria
have been applied. Using strict criteria means that we
may have excluded patients who may genuinely have
idiopathic remitting diabetes, but given our data may
be incomplete in some cases, using strict criteria is
essential.
Conclusion
It is unclear at present what the natural history, rate of
complications, risk of relapse and aetiology is in patients
with idiopathic remitting diabetes. More patients will
need to be identified in order to study this further. In
order to do this, we have found that identifying Remit-
ting Diabetes of unknown aetiology requires the applica-
tion of strict clinical criteria.
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